ANI Pharmaceuticals (ANIP) CEO Lalwani Sells $388K of Stock
ANI Pharmaceuticals President and CEO Nikhil Lalwani sold 5,400 shares worth $388,206 on October 15, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Nikhil Lalwani, PRESIDENT & CEO at ANI Pharmaceuticals, Inc. ($ANIP), sold 5,400 shares at an average price of $71.89, worth about $388,206, on October 15, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $ANIP is up 0.0% to date (from the $72.28 close on Oct 15, 2026).
ANIP
ANI Pharmaceuticals, Inc.
Key Points
- President and CEO Nikhil Lalwani sold 5,400 shares of ANI Pharmaceuticals at $71.89 per share on October 15, 2026, according to a Form 4 SEC filing.
- After the trade, Nikhil Lalwani holds 333,689 $ANIP shares, down 1.59% from before the trade.
- The planned transaction totaled $388,206, following earlier insider sales by other executives at the specialty drug maker.
- The company's next earnings report is scheduled for November 6, 2026, as investors monitor operational results.
Get $ANIP trade alerts by text
We text you when insiders, Congress or big funds trade $ANIP. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated ANI Pharmaceuticals, Inc. alert may contain errors. Disclosures
ANI Pharmaceuticals, Inc. (NasdaqGM: ANIP) President and CEO Nikhil Lalwani sold 5,400 shares of company stock on October 15, 2026. According to a Form 4 filing with the Securities and Exchange Commission, the transaction was executed at a price of $71.89 per share for a total value of $388,206.
Inside Nikhil Lalwani's ANI Pharmaceuticals Trade
The stock sale was carried out under a pre-arranged Rule 10b5-1 trading plan. Following the transaction, the chief executive holds remaining shares directly in the biopharmaceutical firm. ANI Pharmaceuticals shares closed at $72.28 on the day of the sale.
Other Institutional Activity in ANI Pharmaceuticals
Other large funds adjusted their positions in the drug maker during recent quarters. Soleus Capital Management, L.P. lifted its holdings by 47,493 shares, ending with 867,760 shares valued at $62,730,371. American Century Companies Inc grew its stake by 382,900 shares to reach 574,474 shares worth $41,528,725. Meanwhile, Schonfeld Strategic Advisors trimmed its position by 6,377 shares down to 185,629 shares worth about $15,574,273, and Arrowstreet Capital, Limited Partnership cut 2,370 shares to hold 562,016 shares valued at $40,628,137. Tang Capital Management, LLC kept its holdings flat at 707,500 shares worth $51,145,175.
ANI Pharmaceuticals, Inc. Stock Down 0.9%
The shares recently traded around $71.63 as of October 16, 2026, moving below the 50-day moving average of $73.94 and well under the 52-week high of $97.00.
Recent Earnings
The company reported trailing twelve-month revenue of $978.38 million and earnings of $4.62 per share. The firm posted a net profit margin of 11.1% and a return on equity of 20.5%.
Analysts Set New Price Targets
Wall Street maintains an overall buy consensus on the stock with a mean price target of $105.78 across nine analyst opinions.
Insider Buying and Selling at ANI Pharmaceuticals, Inc.
Executive insider selling has continued through recent months. Earlier, CEO Nikhil Suresh Lalwani sold 5,400 shares on September 15, 2026, at $71.00 for $383,400. Chief Financial Officer Stephen P. Carey sold 2,850 shares on September 29, 2026, at $73.00 for $208,050. General Counsel Meredith Cook completed a planned sale of 500 shares on October 13, 2026, at $73.59 for $36,795, following an identical sale by Cook Meredith on the same date.
About ANI Pharmaceuticals
ANI Pharmaceuticals operates as a biopharmaceutical company that develops, manufactures, and markets generic and branded products in the United States and internationally. Its portfolio features specialized items like Cortrophin gel, softgel capsules, injectables, and various prescription treatments.
Bottom Line
Investors will watch for the company's upcoming earnings report on November 6, 2026, to gauge financial progress. Form 4 filings provide ongoing transparency into executive stock transactions.
Related Filing Alerts
Source: Nikhil Lalwani's Form 4 filing on $ANIP (Oct 15, 2026). Read the original filing: Form 4 filing on SEC EDGAR. Written by software, not financial advice. How we make alerts